Antiprogrammed cell death protein 1 immunotherapy for angiosarcoma with high programmed death-ligand 1 expression: a...

Area of Science:

• Oncology
• Immunology

Background:

• Angiosarcoma (AS) is a rare vascular cancer with a poor prognosis and limited treatment options.
• Immunotherapy, particularly targeting the PD-1/PD-L1 pathway, has emerged as a potential treatment modality for various cancers.

Observation:

• This case study focuses on a patient with angiosarcoma and high programmed death-ligand 1 (PD-L1) expression.
• The patient received pembrolizumab, an anti-programmed cell death protein 1 (anti-PD-1) therapy.

Findings:

• Computed tomography (CT) scans revealed a reduction in the size of some angiosarcoma lesions after treatment.
• This suggests a potential clinical benefit from pembrolizumab in this patient.

Implications:

• Early administration of anti-PD-1 therapy could be a promising strategy for angiosarcoma patients.
• High PD-L1 expression may serve as a predictive biomarker for treatment response in angiosarcoma.